XML 61 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Acquisitions - Adapt Narrative (Details)
$ / shares in Units, $ in Millions
6 Months Ended 12 Months Ended
Oct. 15, 2018
USD ($)
employee
$ / shares
shares
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Business Acquisition [Line Items]      
Contingent consideration   $ 10.4 $ 54.4
Goodwill   268.3 $ 259.7
Adapt Pharma      
Business Acquisition [Line Items]      
Number of employees | employee 50    
Common stock issued for acquisition (in shares) | shares 733,309    
Share price (in dollars per share) | $ / shares $ 60.44    
Consideration transferred, equity interests issued and issuable $ 44.3    
Equity $ 37.7    
Lock-up period for adjustment of fair value 2 years    
Fair value of contingent purchase consideration   $ 48.0  
Acquired intangible asset $ 534.0    
Amortization period of intangible asset 15 years    
Present value, discount rate 10.50%    
Acquired in-process research and development $ 41.0    
Goodwill 148.0    
Maximum      
Business Acquisition [Line Items]      
Amortization period of intangible asset   22 years 22 years
Maximum | Adapt Pharma      
Business Acquisition [Line Items]      
Contingent consideration $ 100.0    
IPR&D | Adapt Pharma      
Business Acquisition [Line Items]      
Present value, discount rate 11.00%    
Previously Reported | Adapt Pharma      
Business Acquisition [Line Items]      
Acquired intangible asset $ 534.0    
Goodwill 149.0    
Previously Reported | IPR&D | Adapt Pharma      
Business Acquisition [Line Items]      
Acquired in-process research and development $ 41.0